Keywords: bristol-myers, squibb, maxipime, japan, bristol, pharmaceuticals, kk
Bristol-Myers Squibb's Maxipime in Japan
Article | 11 March 2002
Bristol Pharmaceuticals KK, the Japanese subsidiary of Bristol MyersSquibb, is planning to move in-house sales activities for Maxipime (cefepime) antibiotics ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
